cardiovascular gene therapy (Somatix/Rockefeller)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namecardiovascular gene therapy (Somatix/Rockefeller)
Drug Alias NameAAV (Somatix/Rockfeller)cardiovascular gene therapy (Cell Genesys)AAV
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionSmooth muscle cell proliferation inhibitors
TargetsUpdating
Therapy Area/IndicationsMyocardial InfarctionCoronary RestenosisHeart Failure +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe Rockefeller University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCollateral Therapeutics, IncBiosante Pharmaceuticals IncThe Rockefeller University
Active IndicationsN/A
Inactive IndicationsMyocardial InfarctionCoronary RestenosisHeart Failure +[4] 

Other Information

ATC CodeN/A
Related LinksN/A